Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + cisplatin plus Enzastaurin versus Pemetrexed + cisplatin plus placebo in chemonaive advanced non-small cell lung cancer
2006-005306-31Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pemetrexed + cisplatin + enzastaurin with Pemetrexed + cisplatin + placebo (2 arms). Primary endpoint: Safety of enzastaurin plus pemetrexed and cisplatin (Part 1). Started Jul 2007; status: terminated.
02
Drugs
enzastaurin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-005306-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005306-31.